Table 2.
Preliminary Main Effects Multivariable Regression Model and Final Model
| Preliminary Model | Final Model | |||
|---|---|---|---|---|
| Factor | Hazard Ratio | (95% CI) | Hazard Ratio | (95% CI) |
| Later-generation FQs | 0.45 | (.26–.80) | 0.46 | (.26–.80) |
| Resistance category | ||||
| Susceptible (reference) | 1.00 | … | 1.00 | … |
| Monoresistance to RIF or INH | 1.57 | (.43–5.78) | 1.76 | (.48–6.45) |
| MDR | 3.27 | (1.15–9.30) | 3.23 | (1.11–9.41) |
| Pre-XDR | 5.42 | (2.12–13.9) | 5.31 | (2.02–12.1) |
| XDR | 10.2 | (3.52–29.8) | 9.01 | (3.11–26.1) |
| Study site | ||||
| India (reference) | 1.00 | … | 1.00 | … |
| Moldova | 0.89 | (.31–2.51) | 1.48 | (.79–2.77) |
| South Africa | 1.57 | (.45–5.53) | 1.68 | (.52–5.47) |
| Smear status | 1.91 | (.79–4.64) | … | … |
| BMI <18.5 kg/m2 | 2.21 | (1.25–3.91) | 2.10 | (1.20–3.65) |
| HIV positive (vs negative or unknown) | 2.41 | (.85–6.79) | 2.46 | (.83–7.32) |
| Smoker | 1.23 | (.58–2.59) | … | … |
| Previous TB treatment | 0.66 | (.26–1.67) | … | … |
| Diabetes | 0.87 | (.28–2.70) | … | … |
| Age | 1.01 | (.99–1.03) | … | … |
| Male (vs female) | 1.55 | (.84–2.85) | … | … |
Abbreviations: BMI, body mass index; CI, confidence interval; FQ, fluoroquinolone; HIV, human immunodeficiency virus; INH, isoniazid; MDR, multidrug resistant; RIF, rifampin; TB, tuberculosis; XDR, extensively drug resistant.Values in bold indicate significant differences at the P > .05 level.